At present, there are about 110 million people with diabetes in China, accounting for about one-tenth of the total number of Chinese adults. If you don't take action as soon as possible to reduce risk factors in lifestyles such as unhealthy diets and lack of exercise, the number is expected to increase to 150 million in 2040.
Diabetes is a chronic metabolic disease caused by genetic factors, environmental factors and living habits, which seriously threaten human health. The main reason is that the human pancreas does not produce insulin normally (insulin deficiency) or the body cannot normally use insulin (insulin resistance), resulting in a comprehensive disease in which blood sugar is higher than normal. The main feature of diabetes is hyperglycemia, for which the goal of diabetics is to lower blood sugar levels. Generally speaking, diabetes includes type 1 diabetes and type 2 diabetes. Type 1 diabetes is also known as juvenile diabetes. The cause is unknown. The main feature is that the patient cannot produce enough insulin and needs to use insulin every day. Type 2 diabetes is caused by the inability of the body to use insulin effectively. The number of patients with type 2 diabetes accounts for 90% of the total number of diabetic patients. Overweight and lack of exercise are the main causes.
Diabetes medications mainly include oral hypoglycemic agents, insulin and their analogues. For most patients, oral hypoglycemic agents are economical, practical, and convenient treatments, plus the new base drug list contains five oral diabetes medications, namely acarbose, metformin, glimepiride, Glipizide and glibenclamide, among which acarbose, metformin and glimepiride are commonly used in clinical practice. Therefore, oral hypoglycemic agents accounted for 56.6% of the market share of diabetes drugs, with a market size of 23.36 billion yuan, an increase of 8.8%.
In 2016, the sales of pioglitazone tablets in the three major public hospitals in cities, counties and townships in China were about 660 million yuan. The main manufacturers include Jiangsu Deyuan Pharmaceutical Co., Ltd., Guizhou Tianan Pharmaceutical Co., Ltd., Beijing Tai Yang Pharmaceutical Co., Ltd. and other companies. China has undoubtedly become one of the most burdened countries in the world for diabetes. Preventing and controlling the occurrence and progress of diabetes is an important issue for the public. In the market for oral hypoglycemic agents, the market share of pioglitazone is about 8.2%. It is expected that the whole industry will usher in the development period in the next few years, and the output will reach 640,000 in 2022.